Issue 7, 2019

Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC)

Abstract

A preloaded resin consisting of a thalidomide moiety and an ethylene-oxy linker allows the simple and fast formation of PROTACs. The feasibility of the procedure was illustrated by conjugating different protein kinase inhibitors. The biological functionality of an ibrutinib-like conjugate was then confirmed by a cellular experiment.

Graphical abstract: Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC)

Supplementary files

Article information

Article type
Communication
Submitted
01 Nov 2018
Accepted
17 Dec 2018
First published
17 Dec 2018

Chem. Commun., 2019,55, 929-932

Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC)

S. Krajcovicova, R. Jorda, D. Hendrychova, V. Krystof and M. Soural, Chem. Commun., 2019, 55, 929 DOI: 10.1039/C8CC08716D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements